« Previous
Next »
American Journal of Cardiology
Volume 103, Issue 4
, Pages
437-441
, 15 February 2009
Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event
To access this article, please choose from the options below
This study was supported, in part, by grants from the National Institutes of Health; Dr. Liao was supported by grant HL052233, and Dr. Ganz was supported by grant PO1 HL-48743. Dr. Rawlings was supported by the the Sarnoff Cardiovascular Research Foundation. Dr. Nohria was supported by the American Heart Association, Northeast Affiliate Scientist Development Award 0335439T and the Doris Duke Cardiovascular Foundation. Dr. Liu was supported by the National Health Research Institute and Cardiovascular Research Center of National Cheng Kung Unversity, Tainan, Taiwan. Dr. Creager is the Simon C. Fireman Scholar of Medicine at Brigham and Women's Hospital.
Drs. Nohria and Ganz have research grant support from Pfizer, Inc. Dr. Liao is a consultant for Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, and Asahi-Kasei Pharmaceuticals and receives research support from Pfizer, AstraZeneca, and Boehringer Ingelheim. Dr. Liao is also on the speaker bureau for Merck, Pfizer, AstraZeneca, and Boehringer Ingelheim. Dr. Creager received support from Merck.
PII: S0002-9149(08)01878-X
doi: 10.1016/j.amjcard.2008.10.008
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
American Journal of Cardiology
Volume 103, Issue 4
, Pages
437-441
, 15 February 2009
